When discussing a procedure that uses a human tissue-derived material, look beyond the product name and review its stated origin, available information on donor screening and processing, labeling, traceability records, and consent. Cellinique explains that consultation should review material origin, donor screening, processing, labeling, and traceability records together with consent rather than focusing on the product name. FDA materials describe the U.S. framework for human cells, tissues, and cellular and tissue-based products (HCT/Ps); they do not establish Korean authorization or whether a specific product may be used in Korea.
First ask what the term ‘human tissue-derived’ covers
The phrase alone does not mean that the starting material, degree of processing, intended use, or product classification is the same. At consultation, separate the exact product name, manufacturing or supply information, stated source material, and the proposed site and purpose. An individual-product article such as the Re2O skin-booster guide does not replace consent for the product under discussion.
The FDA describes human cells or tissue intended for implantation, transplantation, infusion, or transfer into a recipient as HCT/Ps and gives examples including bone, skin, corneas, and ligaments. This is a description of U.S. regulation, not a determination of Korean authorization, safety, or indication for a product. (Source: FDA, Tissue & Tissue Products)
Read specific items in consent, not only the product name
Check whether the consent and explanatory materials align on the exact product name, stated material origin, proposed site and purpose, anticipated reactions, and the route for contacting the clinic if a concern occurs. If wording is vague, ask what it means for this product and this proposed use.
Consent is not a promise of an outcome. It is a record for reviewing the scope of material and process, known limits and risks, alternatives, and follow-up contact criteria. If you read the Re2O in-depth effects guide, do not treat it as proof that it applies to you; confirm the material actually proposed and its documentation.
Treat donor screening and processing as information to verify
The FDA explains that, within the U.S. framework, tissue establishments screen and test donors, maintain written procedures, and keep records to reduce the risk of communicable-disease transmission. Its donor-testing page describes U.S. HCT/P donor-testing requirements. Ask what donor-eligibility, screening or testing, processing, and storage information can be provided for the material, but do not read U.S. materials as Korean requirements or a guarantee about an individual product. (Source: FDA, Tissue & Tissue Products; Testing Donors of HCT/Ps)
A statement that screening occurred does not establish that every individual risk is absent. Review the scope of available materials and what allergies, prior reactions, and current health information should be disclosed with the clinician.
Keep labels and traceability records for later questions
Ask whether labels or supplied records can confirm the product name, manufacturing or supply information, lot or other traceability identifier, date of use, and application site. Record formats and what can be supplied vary by material and institutional process, so do not judge suitability by yourself from the absence of one record.
Keep the consent copy, instructions received, material-confirmation information, and follow-up contact details after the procedure. These records do not promise a result or predict an adverse event; they help communicate later symptoms or questions accurately. The procedure-safety guide also outlines general contact principles.
The consultation conclusion depends on the material and individual context
Do not group all human tissue-derived materials into one risk or efficacy category. The actual discussion should consider product documentation, intended site and purpose, prior procedures, allergies, prior reactions, current health status, and available records. Postponement or discussion of other options can also be an appropriate conclusion.
Contact the treating clinic for worsening pain, swelling, warmth, or redness, or for changes outside the guidance you received such as drainage, blisters, or a spreading rash. The consultation information can help organize questions around your material information and health status. This article is general information and does not replace medical care.
Human tissue-derived material consultation checklist
- Confirm the exact product name and manufacturing or supply information.
- Separate stated material origin from the proposed purpose and site.
- Ask what donor-screening or testing and processing or storage information can be provided.
- Confirm labels, lot or traceability identifier, date of use, and application-site records.
- Read consent for risks, limits, alternatives, and contact criteria, then ask questions.
- Do not interpret FDA materials as Korean authorization or a guarantee about an individual product.
Frequently asked questions
Q1. Do all human tissue-derived materials follow the same management framework?
No. Materials, processing, product classification, and intended use can differ. Review the exact product and documents individually.
Q2. Does an FDA source mean Korean authorization has also been confirmed?
No. FDA sources explain U.S. systems and materials. Korean authorization or availability requires separate Korean official information and the actual product documentation.
Q3. What should I review first in consent?
Check whether product name, stated origin, intended site and purpose, known risks and limits, alternatives, and follow-up contact criteria align with this consultation.
Q4. Does donor-screening information mean there is no risk?
No. Screening or testing information alone cannot establish that every risk is absent. Review its scope and your allergies and health status with the clinician.
Q5. Which records are useful after the procedure?
Keep the consent copy, instructions, the available scope of product and traceability information, date and site, and contact details. They help you describe symptoms or questions accurately.
This article provides general information. An individual diagnosis or treatment plan requires a consultation.
